Close search filters
Changing filters will change the listed Success Criteria and Techniques
Category
Topic
Search results (8)
Article
Gene therapies: Million-dollar miracles
August 31, 2023
Gene therapies bring much-needed hope for treating rare conditions, but also concerns, especially around affordability. Learn about strategies plan sponsors can take to address these million-dollar me...
Article
Uncovering behind-the-scenes challenges in bringing gene therapies to market
June 07, 2022
Patients getting access to expensive gene therapies is just one of the many challenges to bringing these sometimes life-saving drugs to market.
Article
How to have a data-driven discussion on gene and cellular therapies
October 28, 2021
As the number of approved gene and cellular therapies grows, you can start preparing your organization now by taking the right next steps.
Article
Innovation in hemophilia drug development and cost-efficiency tools
May 24, 2023
As treatment for hemophilia evolves, data proves a good specialty pharmacy partner can help minimize waste and drive efficient practices.
Article
Three specialty drug trends to prepare for: Biosimilars, gene and cell therapies, cancer drugs
April 20, 2022
Biosimilars, gene and cell therapies, and cancer drugs are filling the specialty pipeline. Here are some insights for each category to help you stay informed.
This topic was the focus of a breakout...
Article
How Evernorth supports specialty patients living with rare diseases
January 22, 2025
Accredo, which is Evernorth’s industry-leading specialty pharmacy, offers decades of condition-specific expertise, a full breadth of clinical support, and a wide variety of patient services.
Article
Two Ways to Assess the Holistic Value of Your Specialty Partner
October 06, 2022
Getting the most value out of your specialty drug management partner starts with asking the right questions.
Article
Copay Assistance Strategy Reduces Financial Burdens for Plans And Patients
October 07, 2021
Innovative solution provides $0 member cost for costly specialty drugs while reducing plans’ costs